Cytokinetics (CYTK) Tops Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Super Micro Computer price target to $39
- Chicago Atlantic Real Estate Finance (REFI) PT Lowered to $16 at Citizens Post Q2 Results
- JPMorgan Upgrades Grupo Aval (AVAL) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
